TearScience, Inc. Lands $15 Million to Bring Novel Dry Eye Treatment to Market
10/4/2011 8:38:28 AM
Medical device company TearScience has secured $15 million in debt financing that the company will use to support a pair of products addressing evaporative dry eye. The venture debt financing comes from Oxford Finance and Silicon Valley Bank (NASDAQ:SIVB). To date, Morrisville, North Carolina-based TearScience has raised more than $70 million in venture capital financing since its 2005 founding. The company’s investors include Essex Woodlands Health Ventures, Investor Growth Capital, General Catalyst, De Novo Ventures, Spray Ventures and Quaker BioVentures.